Training for oncologists to improve communication with lymphoma patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to develop and evaluate a communication training intervention called Hematolo-GIST, specifically designed for hematologic oncologists who treat patients with diffuse large B-cell lymphoma (DLBCL). The intervention focuses on enhancing the ability of oncologists to effectively communicate with their patients regarding their lymphoma diagnosis and advance care planning. Participants will include both oncologists and patients, with the training being implemented during patient appointments. The study seeks to address communication gaps that may impact patient understanding and care decisions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Providers

* Currently a an MSK provider caring for patients with DLBCL (including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and treated as large-cell lymphoma)

Patients

* Per medical record, is currently being treated by a provider who is participating in this study (for the purposes of this study, "treating provider" will be defined as any provider who provides care related to the patient's lymphoma diagnosis)
* Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma
* Per medical record, relapse/ refractory disease within 12 months of 4 cycles of first line therapy OR relapse after 2 cycles of later line therapy or or autologous stem cell transplant (ASCT)
* Self-identify as Black and/or White
* Per medical record, 18 years of age or older
* Per self-report, fluent in English\*\*

  * Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:

    1. How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)
    2. What is your preferred language for healthcare? (must respond English)

Exclusion Criteria:

Providers

* Per self-report, planning to leave the cancer center in the next 12 months

Patients

* Cognitively impaired as demonstrated by (Blessed Orientation- Memory- Concentration (BOMC) score of ≥ 11
* Per research staff judgment and/or self-report, too ill or weak to complete study procedures
* Per medical record or self-report, receiving hospice care at the time of enrollment

Where it's running

• Memorial Sloan Kettering Cancer Center (All protocol activities)
  New York, New York, United States Recruiting
• NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only)
  New York, New York, United States Not yet recruiting

Study contacts

• Principal investigator: Kelly McConnell, PhD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Kelly McConnell, PhD
• Email: McConneK@mskcc.org
• Phone: 646-888-0026

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Glofit-GemOx Bridging to Liso-cel for Relapsed/Refractory Large B-Cell Lymphoma

  This trial tests whether a bridging therapy with Glofit-GemOx followed by lisocabtagene maraleucel helps people with relapsed or refractory large B-cell lymphoma.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT07711483

• MDX2003 for adults with relapsed B‑cell lymphomas

  This trial will test MDX2003 in adults with relapsed or refractory B‑cell lymphomas whose tumors are CD19 or CD20 positive to see if it is safe and can shrink tumors.

  Recruiting at 7 sites Phase 1/2 ModeX Therapeutics, An OPKO Health Company · Richmond, Victoria and 6 other locations · NCT07249905

• Ronde-cel versus standard CD19 CAR T‑cell therapy for relapsed or refractory large B‑cell lymphoma

  This test sees if ronde-cel, a CAR T therapy that targets both CD19 and CD20, works better than currently used CD19 CAR T therapies for adults whose large B‑cell lymphoma returned or did not respond after first‑line treatment.

  Recruiting at 41 sites Phase 3 Lyell Immunopharma, Inc. · Gilbert, Arizona and 43 other locations · NCT07188558

• Evaluating treatment options for posttransplant lymphoproliferative disorder

  This study is testing a combination of rituximab and chemotherapy for patients with high-risk posttransplant lymphoproliferative disorder to see if it helps them better than just using rituximab alone.

  Recruiting Phase 2 Columbia University · Stanford, California and 1 other locations · NCT06954805

• Epcoritamab plus loncastuximab tesirine for relapsed or refractory large B-cell lymphoma

  This test gives epcoritamab together with loncastuximab tesirine to adults whose large B-cell lymphoma has come back or not responded, to see if it can shrink or clear the cancer.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06919939

• Optimizing therapy for newly diagnosed diffuse large B-cell lymphoma using ctDNA

  This study is testing if measuring tumor DNA in the blood during treatment can help people with newly diagnosed diffuse large B-cell lymphoma get less chemotherapy if their cancer shows no signs of activity.

  Recruiting Columbia University · New York, New York · NCT06693830

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.